ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 214

Inflammatory Muscle Disease Associated Pulmonary Hypertension – Clinical Features and Survival At a National Referral Centre

Matthew Webber1, D. Dobarro1, Clive Handler2, Christopher P. Denton3, Benjamin E. Schreiber4 and John G. Coghlan5, 1Pulmonary Hypertension, Royal Free Hospital, London, United Kingdom, 2Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, 3Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 4Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, 5National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Polymyositis/dermatomyositis (PM/DM) and pulmonary complications

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The association between connective tissue disease (CTD) and pulmonary hypertension (PH) is well known, especially in the scleroderma population. However, the association between inflammatory muscle disease (IMD) and PH has not been described in detail.

Methods:

We searched our prospectively collected database of patients undergoing diagnostic right heart catheterization (RHC) from January 2000 to December 2011 for patients with a diagnosis of IMD who had been investigated at the Pulmonary Hypertension Unit, Royal Free Hospital, London (a national tertiary centre). Patient data was sourced from written notes and electronic medical records.

Results:

Of the twenty patients with IMD who underwent RHC at the unit, 17 were diagnosed with PH. Mean age was 61 years and 76% were female with 11 patients diagnosed as dermatomyositis (DM) and 6 as polymyositis (PM). Mean pulmonary artery pressure (mPAP) was 41.2 mmHg with a pulmonary vascular resistance (PVR) of 730.7 (dynes.s.cm-5). Mean 6 minute walk test (6MWT) result was 215 meters and mean NTproBNP values were 176.5 pmol/l. On HRCT scan 70% of patients had evidence of extensive interstitial lung disease (ILD), 24% had limited fibrosis and 1 patient showed no prior evidence of ILD.

Eleven patients went on to receive vasodilator therapies. Of these, 9 underwent repeat RHC at 3-6 months. There was a trend towards improvement: mPAP fell from 40 to 34.2 mmHg (p=0.20) and PVR fell from 704 to 375 dynes.s.cm-5 (p=0.10).

In the 6MWT there was a mean increase of 65.9 meters from baseline to 3-6 months post therapy start date and this improvement was maintained with a mean final result of 380 meters. NTproBNP values showed a weak trend towards reduction, with a fall from 189 to 143 pmol/l (p=0.29) 3-6 months post treatment.

Amongst all 17 patients diagnosed with PH the overall median survival was 41.6 months. In the 12 patients with extensive ILD associated DM/PM the 1, 3 and 5 year survival rates were 75%, 42% and 28% respectively compared to 100%, 75% and 37%  for the 5 patients with limited/no ILD (p=0.19 for difference).

Conclusion:

This analysis is the largest of its kind to assess hemodynamic characteristics and functional response to treatment in this rare group of patients. Patients with IMD who develop PH have shown an improvement in mPAP, PVR, 6MWT and NTproBNP although statistical significance was not reached.

There was no significant difference between outcomes in patients with or without extensive ILD and the survival rates in patients with extensive ILD were higher when compared to a similar group of patients in a regional scleroderma population. Given the young age of some of these patients and the poor prognosis it may be beneficial to consider them for lung transplantation at an early stage in their diagnosis. Despite the poor prognosis however, this observed response to treatment may buy time for pulmonary rehabilitation and the use of combination therapies in patients who are either not eligible or waiting for transplant.


Disclosure:

M. Webber,
None;

D. Dobarro,

Eli Lilly and Company,

;

C. Handler,

Actelion Pharmaceuticals US,

,

Pfizer Inc,

;

C. P. Denton,

Actelion Pharmaceuticals US,

5,

GlaxoSmithKline,

5,

Pfizer Inc,

5,

United Therapeutics,

5;

B. E. Schreiber,

Actelion Pharmaceuticals US,

8, 9,

GSK,

5;

J. G. Coghlan,

GSK,

,

Bayer,

,

Pfizer Inc,

,

Eli Lilly and Company,

.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-muscle-disease-associated-pulmonary-hypertension-clinical-features-and-survival-at-a-national-referral-centre/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology